政治는 아직도 歷史의 中心인가?

Goff, Jacques Le 단국대학교 사학과 학생회 1986 檀史 Vol.2 No.-

정치사가 다른 인문과학들에 의하여 아무리 갱신되고 재생될지라도, 그것은 자율을 바랄 수없다. 하나의 학문분야를 여러부분으로 나누는 것은 전에 보다 더욱 더, 분과다양성(The Age of Pluridisciplinarity)의 시대에는 받아들여질 수 없다. ‘경제ㆍ사회사 연보’의 공동 창간자 중의 한 사람인 루시앙ㆍ페브르의 논평은 과거보다 지금 더욱 진실하다. “경제사 혹은 사회사 같은 것은 없다. 단지 역사가 있다.” 그러나 새로운 일반사의 모델들이 현재의 정치학의 인식론적인 규현인 권력의 현상에 의해서 사회에서 점유되는 바와 똑 같은 위치에서 정치의 차원을 조정시켜야 한다는 것은 아직도 진실이다. 분석의 시대로부터 원자의 시대로 넘어가면서, 정치사는 더 이상 역사의 중추가 아니라 그 핵이다.

ELECTROCHEMICAL PROCESSING OF USED NUCLEAR FUEL

Goff, K.M.,Wass, J.C.,Marsden, K.C.,Teske, G.M. Korean Nuclear Society 2011 Nuclear Engineering and Technology Vol.43 No.4

As part of the Department of Energy's Fuel Cycle Research and Development Program an electrochemical technology employing molten salts is being developed for recycle of metallic fast reactor fuel and treatment of light water reactor oxide fuel to produce a feed for fast reactors. This technology has been deployed for treatment of used fuel from the Experimental Breeder Reactor II (EBR-II) in the Fuel Conditioning Facility, located at the Materials and Fuel Complex of Idaho National Laboratory. This process is based on dry (non-aqueous) technologies that have been developed and demonstrated since the 1960s. These technologies offer potential advantages compared to traditional aqueous separations including: compactness, resistance to radiation effects, criticality control benefits, compatibility with advanced fuel types, and ability to produce low purity products. This paper will summarize the status of electrochemical development and demonstration activities with used nuclear fuel, including preparation of associated high-level waste forms.

Advanced ovarian cancer: what should be the standard of care?

Barbara A. Goff 대한부인종양학회 2013 Journal of Gynecologic Oncology Vol.24 No.1

The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an essential component in the treatment of ovarian cancer; however, the importance of surgical specialization and defining “optimal cytoreduction” as no visible residual disease has been further validated. Ongoing studies are defining the role of neoadjuvant chemotherapy in the upfront treatment of advanced ovarian cancer. In addition,clinical trials are evaluating intraperitoneal, dose dense, antiangiogenic drugs as well as targeted maintenance therapies which will establish new standards of care in the near future.

ELECTROCHEMICAL PROCESSING OF USED NUCLEAR FUEL

K. M. GOFF,J. C. WASS,K. C. MARSDEN,G. M. TESKE 한국원자력학회 2011 Nuclear Engineering and Technology Vol.43 No.4

As part of the Department of Energy’s Fuel Cycle Research and Development Program an electrochemical technology employing molten salts is being developed for recycle of metallic fast reactor fuel and treatment of light water reactor oxide fuel to produce a feed for fast reactors. This technology has been deployed for treatment of used fuel from the Experimental Breeder Reactor II (EBR-II) in the Fuel Conditioning Facility, located at the Materials and Fuel Complex of Idaho National Laboratory. This process is based on dry (non-aqueous) technologies that have been developed and demonstrated since the 1960s. These technologies offer potential advantages compared to traditional aqueous separations including: compactness,resistance to radiation effects, criticality control benefits, compatibility with advanced fuel types, and ability to produce low purity products. This paper will summarize the status of electrochemical development and demonstration activities with used nuclear fuel, including preparation of associated high-level waste forms.

Unique Spectral and Chemical Properties of the various Iron (Ⅱ) porphyrin complexes and their applications in oxidation reaction

유병수 ( H . M . Goff ) 한국공업화학회 1992 한국공업화학회 연구논문 초록집 Vol.1990 No.3

Unique Spectral and Chemical Properties of the various Iron (Ⅱ) porphyrin complexes and their applications in oxidation reaction

유병수 ( H. M. Goff ) 한국공업화학회 1992 한국공업화학회 연구논문 초록집 Vol.1992 No.0

The synthesis and characterization of the unique spectroscopic properties of fluoro - and imidoiron (II) porphyrin complexes and an unusual molecular oxygen reaction with the fluoroiron (II) porphyrin are described. A stable high valent μ- nitrido niduclear iron (IV) porphyrin cationic complex was generated by chemical oxidation of the electron - poor iron tetrakis ( pentafluorophenyl ) porphyrin. Particulary fluorine - 19 NMR spectra of paramagnetic iron porphyrin species are high in information constent, and spectra may be utilized for diagnostic means and analytical value. Regioselective and stereoselective oxidation of unsaturated hydrocarbons by the electron - poor metalloporphyrin complexes will be discussed.

Olefin Polymerization Activity and Crystal Structure of Alkyliron(Ⅲ) Porphyrin Complexes

Oh, Yung-Hee,Swenson, Dale,Goff, Harold M. Korean Chemical Society 2003 Bulletin of the Korean Chemical Society Vol.24 No.2

Alkyliron(Ⅲ) porphyrins, n-butyliron(Ⅲ) tetraphenylporphyrin, (TPP)Fe-Bu and n-butyliron(Ⅲ) tetrakis-(pentafluorophenyl)porphyrin, $(F_{20}TPP)Fe-Bu$ have been evaluated as suitable for olefin free-radical polymerization. Butyl radicals dissociated from n-butyliron(Ⅲ) porphyrin initiated the polymerization reaction, but the ratio of the propagation was low. The GCMS analysis of the reaction mixture of nbutyliron(Ⅲ) porphyrin and styrene has revealed several products containing two butyl groups, while traces of b-hydrogen-abstracted products were observed. The crystal structure of (TPP)Fe-Bu has been determined. The structure of the n-butyliron(Ⅲ) porphyrin reveals the compound containing five-coordinated iron with the average Fe-N distance of 1.973(1) Å and Fe-C of 2.030(2) Å. The iron atom is displaced by 0.137Å from a four nitrogen mean plane. Crystal system is triclinic, and space group is P-1.

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers

Jovana Y. Martin,Renata R. Urban,John B. Liao,Barbara A. Goff 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.5

Objective: Bevacizumab was recently approved by the US Food and Drug Administration foruse in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer(FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimenshave been used; due to concerns for gastrointestinal perforation. We sought to determinebevacizumab-related toxicities in heavily pretreated recurrent EOC. Methods: We performed a retrospective chart review of patients with recurrent EOC, FTC,and PPC from 2001 to 2011. Patients who received at least two prior chemotherapy regimensbefore bevacizumab were included. Medical records were reviewed for bevacizumabassociated toxicities. The Wilcoxon-Mann-Whitney test was used to compare quantitativevariables. Survival was estimated with the Kaplan-Meier method. Results: Sixty patients met inclusion criteria. At the start of bevacizumab treatment, themedian age was 60 years and the median body mass index was 26.5 kg/m2. More than 50%of patients received bevacizumab after three prior cytotoxic regimens. Grade 3 or higherbevacizumab associated toxicity events occurred in four patients, including one patient whodeveloped a rectovaginal fistula. The median overall survival from the start of bevacizumabtreatment was 21.05 months (95% CI, 18.23 to 32.67; range, 1.9 to 110 months). The numberof cytotoxic regimens prior to bevacizumab treatment did not differ in those that experienceda toxicity versus those that did not (p=0.66). Conclusion: The use of bevacizumab in heavily pretreated EOC, FTC, or PPC is worthconsideration.

An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers

Tilley Jenkins Vogel,Abhay Knickerbocker,Chirag A. Shah,Melissa A. Schiff,Christina Isacson,Rochelle L. Garcia,Barbara A. Goff 대한부인종양학회 2015 Journal of Gynecologic Oncology Vol.26 No.1

Objective: Despite the rarity of uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC), theycontribute disproportionately to endometrial cancer deaths. Sufficient clinical information regarding treatment and prognosis islacking. The aim of this study is to evaluate treatment outcomes in a rare cancer cohort based on the experience at two tertiarycare cancer centers. Methods: Clinicopathologic data were retrospectively collected on 279 patients with UPSC and UCCC treated between 1995 to2011. Mode of surgery, use of adjuvant treatment, and dissection of paraaoritc lymph nodes were evaluated for their associationwith overall survival (OS) and progression-free survival (PFS). Results: 40.9% of patients presented with stage I disease, 6.8% of patients presented with stage II disease and 52.3% of patientspresented with stages III and IV. Median follow-up was 31 months (range, 1 to 194 months). OS and PFS at 5 years were 63.0%and 51.9%, respectively. OS and PFS were not affected by mode of surgery (open vs. robotic approach; OS: hazard ratio [HR], 0.68;95% confidence interval [CI], 0.28 to 1.62; PFS: HR, 0.78; 95% CI, 0.40 to 1.56). Adjuvant treatment was associated with improvedOS in stages IB-II (HR, 0.14; 95% CI, 0.02 to 0.78; p=0.026) but not in stage IA disease. There was no difference in OS or PFS basedon the performance of a paraaoritc lymph node dissection. Conclusion: Minimally invasive surgical staging appears a reasonable strategy for patients with non-bulky UPSC and UCCC andwas not associated with diminished survival. Adjuvant treatment improved 5-year survival in stages IB-II disease.